Abstract: Disclosed are a Nested Named Entity Recognition method based on part-of-speech awareness, system, device and storage medium therefor. The method uses a BiLSTM model to extract a feature of text word data in order to obtain a text word depth feature, and each text word of text to be recognized is initialized into a corresponding graph node, and a text heterogeneous graph of the text to be recognized is constructed according to a preset part-of-speech path, the text word data of the graph nodes is updated by an attention mechanism, and the features of all graph nodes of the text heterogeneous graph are extracted using the BiLSTM model, and a nested named entity recognition result is obtained after decoding and annotating. The present disclosure can recognize ordinary entities and nested entities accurately and effectively, and enhance the performance and advantages of the nested named entity recognition model.

Abstract: An improved process for producing 1,5-pentamethylene diisocyanate (PDI) from a cadaverine salt is described herein. The process generally comprises providing a solution comprising a cadaverine salt dissolved in an inert solvent in the presence of a tertiary amine base; and subjecting the solution to a liquid-phase phosgenation reaction to convert the cadaverine to PDI. The phosgenation reaction comprises a step of maintaining the reaction at temperatures between 100° C. and 120° C. for a sufficient time to achieve a desired threshold yield of PDI. The processes described herein enable reductions in the amounts of reactants consumed, reaction temperatures, and/or overall reaction time, as compared to conventional phosgenation reactions. Employing a bio-based cadaverine salt that was not previously subjected to distillation is found to be advantageous, since subjecting cadaverine to high temperatures leads to the formation of certain cyclic compounds that are carried over to the PDI produced.

Abstract: Improved processes for producing bio-based nylon precursors having reduced organic and inorganic impurities are described herein. The processes generally comprise fermenting a microorganism engineered to produce lysine in a modified culture medium having low or reduced inorganic ion content, such as by employing a culture medium having an ammonium dicarboxylate buffering system that is preferably devoid of non-essential inorganic ions, and crystallizing the lysine directly from the spent lysine fermentation supernatant by adding a sufficient amount of a dicarboxylic acid. Such strategies aim to produce lysine dicarboxylate salt crystals that are employable in a downstream bioconversion step for the production of cadaverine dicarboxylate salts having reduced organic and inorganic impurities, which improve their downstream performance, for example in polymeration reactions for polyamide synthesis.

Abstract: Provided is a method for preparing ?-alanine, the method comprising: preparing a ?-alanine product from a reactant containing fumaric acid and aqueous ammonia in the presence of a catalyst, wherein the catalyst contains a catalyst composition containing aspartase and L-aspartic acid-?-decarboxylase, and adding fumaric acid during the reaction, wherein the total moles of the fumaric acid added is equal to the initial moles of the aqueous ammonia in the reactant minus the initial moles of the fumaric acid in the reactant. Also provided are methods for preparing a ?-alanine salt (in particular calcium ?-alanine, sodium ?-alanine, and potassium ?-alanine) and a pantothenate (in particular calcium pantothenate, sodium pantothenate, and potassium pantothenate).

Abstract: The presently disclosed subject matter provides recombinant dopaminergic neurons and/or recombinant progenitors thereof that include one or more transgenes encoding a nurr-1 polypeptide, a pitx3 polypeptide, an Imxi a polypeptide, a biologically active fragment thereof, a biologically active derivative thereof, and/or any combination thereof. Also provided are methods for producing a recombinant dopaminergic neuron or recombinant progenitor thereof, methods for producing lineage primed cells, methods for ameliorating at least one symptom associated with a neurological disorder, methods for transplantation, methods for inducing growth, repair, ancllor regeneration of a neuron, for delivering a cytokine or a growth factor to the central nervous system, methods for providing a dopaminergic neuron function, and cell cultures that include recombinant olfactory epithelial-derived stem cells and/or a differentiated derivatives thereof.

Abstract: The present application describes the use of adult human olfactory neuroepithelium (ONe) stem cells in the treatment of diabetes.

Abstract: The presently disclosed subject matter provides recombinant dopaminergic neurons and/or recombinant progenitors thereof that include one or more transgenes encoding a nurr-1 polypeptide, a pitx3 polypeptide, an Imxi a polypeptide, a biologically active fragment thereof, a biologically active derivative thereof, and/or any combination thereof. Also provided are methods for producing a recombinant dopaminergic neuron or recombinant progenitor thereof, methods for producing lineage primed cells, methods for ameliorating at least one symptom associated with a neurological disorder, methods for transplantation, methods for inducing growth, repair, and/or regeneration of a neuron, for delivering a cytokine or a growth factor to the central nervous system, methods for providing a dopaminergic neuron function, and cell cultures that include recombinant olfactory epithelial-derived stem cells and/or a differentiated derivatives thereof.

Abstract: An isolated human olfactory stem cell can be prepared by culturing human tissue from olfactory neuroepithelium to form neurospheres.

Abstract: An isolated human olfactory stem cell can be prepared by culturing human tissue from olfactory neuroepithelium to form neurospheres.

Abstract: A method of transplantation that includes lineage priming human progenitor cells, to form lineage primed cells and transplanting the lineage primed cells into a patient. The lineage primed cells are selected from the group consisting of oligodendrocytic lineage primed cells, dopaminergic lineage primed cells, and motoneuronal lineage primed cells, and lineage priming has an efficiency of at least 1%.